Skip to content
Review Open access

The 5-Lipoxygenase Pathway in Ovarian Cancer: Mechanisms of Metastasis, Chemoresistance, and Translational Targeting

Sep 2026 · International Journal of Women's Health · Vol 18 · 0 citations · 26 references
Medicine

Abstract

Abstract Ovarian cancer remains one of the most lethal gynecologic malignancies, characterized by early peritoneal dissemination, extensive microenvironmental remodeling, and frequent emergence of chemoresistance. Beyond genetic alterations, dysregulated lipid mediator signaling represents a regulatory layer that links inflammation, invasion, immune evasion, and cellular stress adaptation. The 5-lipoxygenase (5-LOX, encoded by ALOX5) pathway converts arachidonic acid into bioactive leukotrienes through coordinated activity with 5-LOX-activating protein (FLAP, encoded by ALOX5AP), thereby activating G protein-coupled receptors, including BLT1, BLT2, and cysteinyl leukotriene receptors. This narrative review synthesizes preclinical, translational, and clinical-association evidence for 5-LOX signaling in ovarian cancer. Particular attention is given to BLT2-driven invasion and chemoresistance, hypoxia-induced leukotriene production, macrophage recruitment, ALOX5AP-associated immune suppression, and biomarker-guided therapeutic development. The available evidence supports the 5-LOX axis as a biologically relevant but still clinically immature target. Future development should prioritize compartment-resolved pathway mapping, functional validation in patient-derived models and immune-competent experimental systems, and rational combination strategies rather than unselected monotherapy.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.